CureVac NV (MIL:1CVAC) Long-Term Capital Lease Obligation : €32.2 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is CureVac NV Long-Term Capital Lease Obligation?

CureVac NV's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €32.2 Mil.

CureVac NV's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (€34.9 Mil) to Dec. 2024 (€33.6 Mil) and declined from Dec. 2024 (€33.6 Mil) to Mar. 2025 (€32.2 Mil).

CureVac NV's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (€37.1 Mil) to Dec. 2023 (€36.8 Mil) and declined from Dec. 2023 (€36.8 Mil) to Dec. 2024 (€33.6 Mil).

CureVac NV Long-Term Capital Lease Obligation Historical Data

The historical data trend for CureVac NV's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Long-Term Capital Lease Obligation Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

26.85

25.42

37.11

36.82

33.64

CureVac NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															35.55	33.96	34.90	33.64	32.18

CureVac NV (MIL:1CVAC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

CureVac NV Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CureVac NV's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (MIL:1CVAC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CVAC:USA 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines